Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial

Am Heart J. 2020 Nov:229:100-109. doi: 10.1016/j.ahj.2020.08.007. Epub 2020 Aug 18.

Abstract

Background: Myocardial infarction (MI) in elderly patients is associated with unfavorable prognosis, and it is becoming an increasingly prevalent condition. The prognosis of elderly patients is equally impaired in ST-segment elevation (STE) or non-STE (NSTE), and it is markedly worsened by the common presence of multivessel disease (MVD). Given the limited evidence available for elderly patients, it has not yet been established whether, as for younger patients, a complete revascularization strategy in MI patients with MVD should be advocated. We present the design of a dedicated study that will address this research gap.

Methods and design: The FIRE trial is a prospective, randomized, international, multicenter, open-label study with blinded adjudicated evaluation of outcomes. Patients aged 75 years and older, with MI (either STE or NSTE), MVD at coronary artery angiography, and a clear culprit lesion will be randomized to culprit-only treatment or to physiology-guided complete revascularization. The primary end point will be the patient-oriented composite end point of all-cause death, any MI, any stroke, and any revascularization at 1 year. The key secondary end point will be the composite of cardiovascular death and MI. Quality of life and physical performance will be evaluated as well. All components of the primary and key secondary outcome will be tested also at 3 and 5 years. The sample size for the study is 1,400 patients.

Implications: The FIRE trial will provide evidence on whether a specific revascularization strategy should be applied to elderly patients presenting MI and MVD to improve their clinical outcomes.

Trial registration: ClinicalTrials.gov NCT03772743.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Aged
  • Cardiovascular Agents / therapeutic use*
  • Conservative Treatment / methods
  • Coronary Angiography / methods
  • Female
  • Functional Status
  • Humans
  • Male
  • Mortality
  • Multicenter Studies as Topic
  • Myocardial Revascularization* / adverse effects
  • Myocardial Revascularization* / methods
  • Non-ST Elevated Myocardial Infarction* / mortality
  • Non-ST Elevated Myocardial Infarction* / surgery
  • Postoperative Complications* / diagnosis
  • Postoperative Complications* / etiology
  • Prognosis
  • Randomized Controlled Trials as Topic
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / mortality
  • ST Elevation Myocardial Infarction* / surgery
  • Severity of Illness Index

Substances

  • Cardiovascular Agents

Associated data

  • ClinicalTrials.gov/NCT03772743